Post by: Colleen Parr Dekker
- Fourth Quarter 2023 Financial Results:
- Revenue of $1,035 million
- Reported Net Loss of $141 million, Adjusted Net Income of $39 million
- Adjusted EBITDA of $165 million or 15.9% of Revenue
- Reported EPS of $(0.29), Adjusted EPS of $0.08
- Net leverage ratio of 5.6x Adjusted EBITDA
- Full Year 2023 Financial Results:
- Revenue of $4,417 million
- Reported Net Loss of $1,231 million, Adjusted Net Income of $439 million
- Adjusted EBITDA of $979 million or 22.2% of Revenue
- Reported EPS of $(2.50), Adjusted EPS of $0.89
- Full Year 2024 Guidance:
- Revenue of $4,450 to $4,540 million
- Reported Net Loss of $17 to $62 million, Adjusted EBITDA of $960 to $1,010 million
- Reported EPS of $(0.12) to $(0.03), Adjusted EPS of $0.87 to $0.95
- Guidance includes full year contribution of the company's aqua business and does not consider contribution from expected launches of three blockbuster-potential products
- Announced strategic restructuring impacting approximately 420 personnel, resulting in a charge to 2024 reported results of $50 to $55 million and generating approximately $30 to $35 million in annualized savings, which the company plans to reinvest in more significant value creation opportunities
GREENFIELD, IN (February 26, 2024) - Elanco Animal Health Incorporated (NYSE: ELAN) today reported its financial results for the fourth quarter and full year 2023 and provided initial guidance both for the first quarter and full year 2024.
